Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How Accurate Is Point-of-Care Ultrasound for Detecting Pediatric Elbow Fractures Presenting to the Emergency Department?: A Systematic Review and Meta-Analysis.

Pediatric emergency care·2026
Same author

Abdominal POCUS in the paediatric emergency department: how does UK use relate to that overseas? A snapshot PERUKI survey.

Archives of disease in childhood·2026
Same author

Psychiatric comorbidities and sexual health risks in HIV-serodiscordant heterosexual couples involving women with borderline personality disorder: a mixed-method study and theoretical modeling.

Frontiers in psychiatry·2026
Same author

An evaluation of National Health Service health checks delivered by paramedics in the community.

Journal of public health (Oxford, England)·2026
Same author

Evaluating the diagnostic accuracy of point-of-care ultrasound for paediatric appendicitis: a UK multicentre observational study.

Archives of disease in childhood·2025
Same author

How accurate is point-of-care ultrasound for detecting paediatric appendicitis? A systematic review and meta-analysis.

Archives of disease in childhood·2025

Related Experiment Video

Updated: Jun 5, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Risk stratification for benign prostatic hyperplasia (BPH) treatment.

Mark Emberton1, John M Fitzpatrick, Jon Rees

  • 1University College Hospital, London, Backwell, UK.

BJU International
|January 27, 2011
PubMed
Summary

Benign prostatic hyperplasia (BPH) management has evolved. Combined alpha-blocker and 5ARI therapy significantly reduces disease progression and complications, shifting focus to primary care and shared treatment strategies.

More Related Videos

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Area of Science:

  • Urology
  • Pharmacology
  • Health Services Research

Background:

  • Benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms, historically managed with monotherapy until surgery.
  • Past treatments focused on symptom relief using alpha-blockers or 5-alpha-reductase inhibitors (5ARIs).

Purpose of the Study:

  • To evaluate the efficacy of combined alpha-blocker and 5ARI therapy for BPH.
  • To assess the impact of risk stratification and evidence-based treatment on BPH progression and complications.
  • To explore future management strategies in primary care settings.

Main Methods:

  • Review of large randomized trials on BPH treatment.
  • Analysis of evidence supporting combined alpha-blocker/5ARI therapy versus monotherapy.
  • Examination of disease progression and long-term complication rates.

Main Results:

  • Combined alpha-blocker and 5ARI therapy significantly reduces BPH disease progression.
  • This combination therapy decreases the risk of acute urinary retention and the need for surgery.
  • Evidence supports risk stratification for tailored BPH management.

Conclusions:

  • Combined alpha-blocker/5ARI therapy offers superior outcomes for BPH compared to monotherapy.
  • Future BPH management will increasingly involve primary care with shared care models.
  • Optimizing resource use and expertise requires collaboration between primary and secondary care sectors.